Want to see OTLK full AI Analyst Report?
OTLK Stock Chart & Stats
$0.31
-$0.17(-7.61%)
At close: 4:00 PM EST
$0.31
-$0.17(-7.61%)
Day’s Range― - ―
52-Week Range$0.16 - $3.39
Previous CloseN/A
Volume358.39K
Average Volume (3M)32.16M
Market Cap
$232.22M
Enterprise Value$87.32M
Total Cash (Recent Filing)$7.75M
Total Debt (Recent Filing)$27.19M
Price to Earnings (P/E)―
Beta1.41
Next Earnings
Aug 13, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.36
Shares Outstanding160,148,560
10 Day Avg. Volume24,275,783
30 Day Avg. Volume32,156,172
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-1.15
Price to Sales (P/S)26.09
P/FCF Ratio-0.71
Enterprise Value/Market Cap0.38
Enterprise Value/Revenue262.12
Enterprise Value/Gross Profit-72.64
Enterprise Value/Ebitda-1.41
Forecast
1Y Price Target
$4.04Price Target Upside1202.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.48
Revenue Forecast (FY)$16.01M
Bulls Say, Bears Say
Bulls Say
Regulatory Approval PotentialFDA acceptance with a Class 1 review and a defined PDUFA date meaningfully advances ONS-5010 toward potential approval. If cleared as the first FDA‑approved ophthalmic bevacizumab, the company would gain durable market positioning, broaden patient access, and create a structural commercial opportunity in retinal care.
Regulatory Validation Via AppealThe successful FDA appeal and Office of New Drugs conclusion that trials provide substantial evidence reduces the need for further pivotal studies. This regulatory validation lowers clinical and program execution risk, shortens time to potential launch and supports the long‑term commercial viability of the lead asset.
Access To Capital MarketsAn active shelf registration and a $100M ATM give Outlook structural flexibility to fund regulatory work, pre‑launch activities, and initial commercialization without needing bespoke financings. Ongoing market access is a durable operational lever to bridge clinical-stage cash needs through potential product launch.
Bears Say
Negative Shareholder EquityChronic negative shareholder equity reflects accumulated losses that have eroded the capital base, weakening financial flexibility. This structural balance‑sheet impairment limits secured borrowing capacity, raises insolvency risk in stress scenarios, and constrains strategic options over the medium term.
Ongoing Cash BurnConsistent negative operating and free cash flows show the business cannot self‑fund development or commercialization. Persistent cash burn forces reliance on external funding, increases execution risk for a commercial launch, and creates runway uncertainty absent successful financing or near‑term approval.
Repeated Dilutive FinancingsFrequent registered directs, ATM capacity, and warrant repricings signal structural dependence on dilutive equity to finance operations. This pattern increases potential long‑term share count, creates investor overhang, can dilute future earnings power per share, and may hamper alignment with long‑term shareholders.
Outlook Therapeutics News
OTLK FAQ
What was Outlook Therapeutics’s price range in the past 12 months?
Outlook Therapeutics lowest stock price was $0.16 and its highest was $3.39 in the past 12 months.
What is Outlook Therapeutics’s market cap?
Outlook Therapeutics’s market cap is $232.22M.
When is Outlook Therapeutics’s upcoming earnings report date?
Outlook Therapeutics’s upcoming earnings report date is Aug 13, 2026 which is in 39 days.
How were Outlook Therapeutics’s earnings last quarter?
Outlook Therapeutics released its earnings results on May 15, 2026. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.121 by -$0.039.
Is Outlook Therapeutics overvalued?
According to Wall Street analysts Outlook Therapeutics’s price is currently Undervalued.
Does Outlook Therapeutics pay dividends?
Outlook Therapeutics does not currently pay dividends.
What is Outlook Therapeutics’s EPS estimate?
Outlook Therapeutics’s EPS estimate is -0.1.
How many shares outstanding does Outlook Therapeutics have?
Outlook Therapeutics has 160,148,560 shares outstanding.
What happened to Outlook Therapeutics’s price movement after its last earnings report?
Outlook Therapeutics reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.121. Following the earnings report the stock price went up 0.439%.
Which hedge fund is a major shareholder of Outlook Therapeutics?
Currently, no hedge funds are holding shares in OTLK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Outlook Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.04 (1202.15% Upside)
$4.04 (1202.15% Upside)
Blogger Sentiment
Bullish
OTLK Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 151.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $5.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 23.8%
Last 30 Days ▲ 23.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-15.20%
12-Months-Change
Fundamentals
Return on Equity
178.08%
Trailing 12-Months
Asset Growth
14.77%
Trailing 12-Months
Company Description
Outlook Therapeutics
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.
OTLK Stock 12 Month Forecast
Average Price Target
$4.04
▲(1202.15% Upside)
Technical Analysis
Ownership Overview
14.18% Insiders
1.41% Mutual Funds
3.51% Other Institutional Investors
79.79% Public Companies and
Individual Investors